Abstract
Spinal cord injury (SCI)-related osteoporosis is common complication in people with tetraplegia or paraplegia. Studies have shown that sublesional regions are severely demineralized. Loss of bone and sequential fractures are major problems in people with SCI that lead to further immobilization and decreasing quality of life. Despite extensive research mechanisms of this bone impairment are inadequately understood. This article discusses basics of bone metabolism physiopathology along with pharmaceutical prevention and treatment approaches to manage acute SCI-related bone loss.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Garland DE, Adkins RH, Stewart CA. Bone Impairment and Spinal Cord Injury. In: Stone JH, Blouin M, editors. International Encyclopedia of Rehabilitation; 2013. http://cirrie.buffalo.edu/encyclopedia/en/article/108/.
Dionyssiotis Y. Spinal cord injury-related bone impairment and fractures: an update on epidemiology and physiopathological mechanisms. J Musculoskelet Neuron Interact. 2011;11:257–65.
Schiessl H, Ferretti JL, Tysarczyk-Niemeyer G, Willnecker J. The role of the muscles to the mechanical adaptation of bone. In: Lyritis GP, (ed). Advances in osteoporosis, vol.1. Athens: Hylonome Editions; 1998. p. 63–71.
Maimoun L, Fattal C, Micallef JP, Peruchon E, Rabischong P. Bone loss in spinal cord-injured patients: from physiopathology to therapy. Spinal Cord. 2006;44:203–10.
Soleyman-Jahi S, Yousefian A, Maheronnaghsh R, Shokraneh F, Zadegan SA, Soltani A, et al. Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review. Eur Spine J. 2018;27:1798–14.
Wilmet E, Ismail AA, Heilporn A, Welraeds D, Bergmann. Longitudinal study of the bone mineral content and of soft tissue composition after spinal cord injury. Paraplegia. 1995;33:674–7.
Uebelhart D, Demiaux-Domenech B, Roth M, Chantraine A. Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilisation. A review. Paraplegia. 1995;33:669–73.
Elias AN, Gwinup G. Immobilization osteoporosis in paraplegia. J Am Paraplegia Soc. 1992;15:163–70.
Bauman WA, Garland DE, Schwartz E. Calcium metabolism and osteoporosis in individuals with spinal cord injury. Top Spinal Cord Inj Rehabil. 1997;2:84–96.
Naftchi NE, Viau AT, Sell GH, Lowman EW. Mineral metabolism in spinal cordinju ry. Arch Phys Med Rehabil. 1980;61:139–42.
Bauman WA, Cardozo CP. Osteoporosis in individuals with spinal cord injury. PMR. 2015;7:188–201.
Meythaler JM, Tuel SM, Cross LL. Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. Arch Phys Med Rehabil. 1993;74:316–9.
Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558–67.
Maynard FM. Immobilization hypercalcemia following spinal cord injury. Arch Phys Med Rehabil. 1986;67:41–4.
Bauman WA, Wecht JM, Kirshblum S, Spungen AM, Morrison N, Cirnigliaro C, et al. Effect of pamidronate administration on bone in patients with acute spinal cord injury. J Rehabil Res Dev. 2005;42:305–13.
Battaglino RA, Lazzari AA, Garshick E, Morse LR. Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies. Curr Osteoporos Rep. 2012;10:278–85.
Pearson EG, Nance PW, Leslie WD, Ludwig S. Cyclical etidronate: its effect on bone density in patients with acute spinal cord injury. Arch Phys Med Rehabil. 1997;78:269–72.
Nance PW, Schryvers O, Leslie W, Ludwig S, Krahn J, Uebelhart D. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Arch Phys Med Rehabil. 1999;80:243–51.
Zehnder Y, Risi S, Michel D, Knecht H, Perrelet R, Kraenzlin M, et al. Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res. 2004;19:1067–74.
Chappard D, Minaire P, Privat C, Berard E, MendozaSarmiento J, Tournebise H, et al. Effects of tiludronate on bone loss in paraplegic patients. J Bone Miner Res. 1995;10:112–18.
Bubbear JS, Gall A, Middleton FR, Ferguson-Pell M, Swaminathan R, Keen RW. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int. 2011;22:271–9.
Shapiro J, Smith B, Beck T, Ballard P, Dapthary M, BrintzenhofeSzoc K, et al. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int. 2007;80:316–22.
Schnitzer TJ, Kim K, Marks J, Yeasted R, Simonian N, Chen D. Zoledronic acid treatment after acute spinal cord injury: results of a randomized, placebo-controlled pilot. Trial PMR. 2016;8:833–43.
Gifre L, Vidal J, Carrasco JL, Muxi A, Portell E, Monegal A, et al. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury. Osteoporos Int. 2016;27:405–10.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The author declares no financial interest in relation to the work described.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Dionyssiotis, Y. Is prophylaxis for osteoporosis indicated after acute spinal cord injury?. Spinal Cord Ser Cases 5, 24 (2019). https://doi.org/10.1038/s41394-019-0167-y
Received:
Revised:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1038/s41394-019-0167-y
This article is cited by
-
A pulse survey: assessment and management of bone loss in spinal cord injury
Spinal Cord Series and Cases (2021)
-
Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients’ Quality of Life
Current Osteoporosis Reports (2020)
-
Osteoporosis in Veterans with Spinal Cord Injury: an Overview of Pathophysiology, Diagnosis, and Treatments
Clinical Reviews in Bone and Mineral Metabolism (2019)
